medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2011, Número 07-08

<< Anterior Siguiente >>

Medicina & Laboratorio 2011; 17 (07-08)


Guía de atención de la lepra
Ministerio de la Protección Social

Idioma: Español
Referencias bibliográficas: 48
Paginas: 359-388
Archivo PDF: 737.93 Kb.


FRAGMENTO

La lepra es una enfermedad infecciosa con probable susceptibilidad genética y de larga evolución, que se transmite por el contacto directo y prolongado con pacientes de las formas abiertas (bacilíferos) y afecta múltiples órganos causando secuelas en ocasiones irreversibles. La actualización de la Guía de atención de la lepra constituye un conjunto de recomendaciones asistenciales que intentan proporcionar información acerca del diagnóstico y tratamiento del paciente con lepra.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. WHO. Expert Committee on Leprosy, 7th Report, 1998: 1-43.

  2. Faizal M. La lepra. Universidad Nacional de Colombia. Servicio de biblioteca virtual. www.unal.edu.co

  3. Guerrero M, Arias MT, Garcés MT, León CI. Desarrollo y aplicación de una prueba de RCP para detectar la infección subclínica por Mycobacterium leprae. Rev Panam Salud Pública; 11(4); 2002: 228-233.

  4. World Health Organization. Chemotherapy of leprosy. Disponible en: http:// www.who.int/lep/reports/trs847. Pdf. Acceso el 5 de julio de 2004.

  5. SIVIGILA. Boletín epidemiológico. 2004.

  6. Hastings RC, editor. Leprosy. Edinburgh: Churchill Livingstone; 1994.

  7. Thalhari S, Garrido N R. Hanseníase. Instituto superior de estudos da Amazõnia 1989.

  8. Jacobson RR, Krahenbuhl JL. Leprosy. Lancet 1999; 353: 655-60.

  9. Ottenhoff THM. Immunology of leprosy: lesson from and for xxx rosy [editorial]. Int J Lepr 1994; 62: 108-21.

  10. Meyer CG, May J Stark K. Human leukocyte antigens in tuberculosis and leprosy. Trends Microbiol 1998; 6: 148-53.

  11. Ridley D. Pathogenesis of leprosies and related diseases. Butterw & co 1998.

  12. Freeedman VH, Weinstein DE, Kaplan G. How Mycobacterium leprae infects peripheral nerves. Lepr Rev 1999; 70: 136-9.

  13. Charosky CB. Cardama JE. Neuropathies in hansen’s disease. Int J Leprosy 1983: 51: 576-86.

  14. Brazis PW. Masdeu JC, Biller J. Localization in clinical neurology. Second edition. Little, Brown and Company; 1990; 3.

  15. Low PH. Disease of peripheral nerves in clinical neurology. Lippincott- Raven Publisher. 1994.

  16. Liwen D. Diagnostic exploration of enlarged peripheral nerves in suspected cases of leprosy: An analysis of 55. cases. Lepr Rev 1992; 63: 141-4.

  17. Ebenezer GJ, Suneetha S, Mohandas R Arunthathi S. Multibacillary nerve histology in clinically diagnosed dordeline tuberculoid leprosy patients. Int J Lepr 1996; 64: 311-5.

  18. Rameshh G., Ramana P.V. et al. Two unusual nerve abscesses – lepromatous leprosy and pure neural leprosy: case reports. Lepr Rev 1996; 67: 217-221.

  19. Lienhardt C, Fine P E M. Type 1 reaction, neuritis and disability in Leprosy: what is the current epidemiological situation? Lepr Rev 1994; 65: 190-203.

  20. Job CK, jayakumar J, Williams DL, Gillis TP. Role of polymerase chain reaction in the diagnosis of early leprosy. Int J Lepr Other Mycobact Dis 1997; 65: 461-464.

  21. Santos AR, De Miranda AB, Sarno EN, Suffys PN, Degrave WM. Use of RCP – mediated amplification of Mycobacterium leprae DNA in different types of clinical samples for the diagnosis of leprosy. J Med Microbiol 1993;39: 298-304;43.

  22. Wolcott MJ. Advances in nucleic acid-based detection methds. Cliun Microbiol Rev 1992; 5: 370-386,44.

  23. Erlich HA, Gelfand DH, Saiki RK. Specific DNA amplification. Nature 1988; 331: 461-462,45.

  24. Williams D, Gillis T. Molecular Detection of Drug Resistance in Mycobacterium Leprae. Lepr Rev 2004; 75: 118-130.

  25. Jennekens F, Schinkel A. Neurological examination of patients suffering from leprosy: is it worthwhile? Lepr Rev 1992; 63: 269-73.

  26. Van Brakel W. Shute J, Dixon J, Arzet H. Evaluation of sensibility in leprosycomparison of various clinical methods. Lepr Rev 1994; 65: 106-21.

  27. Mahajan PM; DG Jogaikar, Mehta JM. A study of pure neuritic leprosy: clinical experience. Indian J Lepr 1996; 68 (2): 137-141.

  28. Menicucci LA, Miranda A, Gomes Antunes SL, Rodríguez M. Microscopic Leprosy Skin Lesions In Primary Neuritis Leprosy. Journal of the American Academy of Dermatology 2004; 52: 648-652.

  29. Britton W, Lockwood D. Leprosy. Lancet 2004; 363: 1209-19.

  30. Moschella S. An update on the diagnosis and treatment of leprosy. Journal of the American Academy of Dermatology. 2004; 51: 417-26.

  31. Honore N, Perrani E, Telenti A, Grosset J, Cole ST. A simple and rapid technique for the detection of rifampin resistance in Mycobacterium leprae Int J Lepr Other Mycobact Dis 1993; 61: 600-604.

  32. Cambau E, Perani E, Guillemin I, Jamet P, Ji B. Multidrug – resístance to dapsone, rifampicin and ofloxacin in mycobacterium leprae. Lancet 1997; 349: 103-104.

  33. Richardus J, Nicholls P. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. International Journal of Epidemiology 2004; 33: 337-343.

  34. Galvis V, Bustamante M. Guía de atención de la lepra. Ministerio de salud Colombia; dirección general de promoción y prevención. 1999.

  35. Leiker D.L., McDougall A.C. Guia técnico Baciloscopia Da Hanseníase Talmilep, 2da edición, 1987.

  36. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targerted intervention. Lepra Review, 2004; 34: 310-326.

  37. Shumin C, Zhang L, Diagchang L, Bing L. Should contanct examination in a low endemic situation of leprosy continue? International Journal of leprosy 2003; 71 (2): 95-100.

  38. Douglas J T, Celliona R V, Fajardo T T, Abalos R M. Prospective study of serological conversión as a risk factor for development of leprosy among household contacts. Clinical and diagnostic laboratory immunology 2004; 11 (5): 897-900.

  39. Ji B. Why Multidrug Theraphy for multibacillary leprosy can be shortened for 12 months. Lepra Review 1998; 69: 106–109.

  40. Britton W J, Lockwood D. Leprosy. Lancet 2004; 363: 1209–1219

  41. Normas tecnicas e procedimentos para utilizacao dos esquemas de poliquimioterapia No tratamento Da Hanseníase. Ministerio da Saúde Secretaria Nacional Divisão Nacional de Programas Especiais De Saúde Divisão Nacional De Dermatologia Sanitária. Brasília Brasil.

  42. Klioze A, Ramos-Caro F. Visceral Leprosy. International Journal Of Dermatology 2000; 39: 641–658.

  43. Kontochristopoulos G, Kyriakis K, Symeonidou S. Squamous cell carcinoma in chronic trophic ulcers of leprosy patients. Journal Of The European Academy Of Dermatology And Venereology 2000; 14: 222-236.

  44. John S, Roul RK, Anderson GA. Cancer associated with Leprosy. Indian Journal Of leprosy 1994; 66 (3): 321-325.

  45. Bobhate SK, Madankar ST, Parate SN, Choudhary RK, Kumbhalkar DT. Malignant transformation of plantar ulcers in leprosy. Indian Journal Of Leprosy 1993; 65 (3): 297-303.

  46. Richardus JH, Smith TC. Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases 1991; 62 (4): 381-388.

  47. Gift N, Geetha J, Joseph R. Relapses in multibacillary patients treated with multidrug therapy until smear negative: Findings after twenty years. International Journal Of Leprosy 2004; 72 (1): 1-7

  48. Gillis W. Psychiatric aspects of Hansen disease. J Clin Psychiatry. Dec 1987;48(12): 470-79. 49. Bharath S, Shamasundar C. Correlates of Psychiatric morbidity in patients with leprosy. Indian J Lepr. Jul 2001; 73 (3): 217-28.




2020     |     www.medigraphic.com